EA036335B1 - Связывающие icos белки - Google Patents

Info

Publication number

EA036335B1

EA036335B1 EA201791706A EA201791706A EA036335B1 EA 036335 B1 EA036335 B1 EA 036335B1 EA 201791706 A EA201791706 A EA 201791706A EA 201791706 A EA201791706 A EA 201791706A EA 036335 B1 EA036335 B1 EA 036335B1

Authority

EA

Eurasian Patent Office

Prior art keywords

icos

seq

binding protein

cell

cells

Prior art date

2015-01-28

Links

• Espacenet
• Global Dossier
• Discuss

• 102000014914 Carrier Proteins Human genes 0.000 title claims abstract description 150
• 108091008324 binding proteins Proteins 0.000 title claims abstract description 150
• 230000027455 binding Effects 0.000 claims abstract description 224
• 239000000427 antigen Substances 0.000 claims abstract description 144
• 108091007433 antigens Proteins 0.000 claims abstract description 143
• 102000036639 antigens Human genes 0.000 claims abstract description 143
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 137
• 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 131
• 238000000034 method Methods 0.000 claims abstract description 91
• 201000011510 cancer Diseases 0.000 claims abstract description 82
• 239000000556 agonist Substances 0.000 claims abstract description 36
• 208000015181 infectious disease Diseases 0.000 claims abstract description 28
• 206010040047 Sepsis Diseases 0.000 claims abstract description 22
• 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 claims abstract description 21
• 102000043396 human ICOS Human genes 0.000 claims abstract description 19
• 208000035473 Communicable disease Diseases 0.000 claims abstract description 16
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 13
• 230000001939 inductive effect Effects 0.000 claims abstract description 10
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 87
• 238000011282 treatment Methods 0.000 claims description 87
• 108090000623 proteins and genes Proteins 0.000 claims description 79
• 102000004169 proteins and genes Human genes 0.000 claims description 68
• 239000003795 chemical substances by application Substances 0.000 claims description 34
• 239000002246 antineoplastic agent Substances 0.000 claims description 30
• 239000008194 pharmaceutical composition Substances 0.000 claims description 21
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
• 201000010099 disease Diseases 0.000 claims description 15
• 229940034982 antineoplastic agent Drugs 0.000 claims description 14
• 230000003308 immunostimulating effect Effects 0.000 claims description 14
• 230000002519 immonomodulatory effect Effects 0.000 claims description 13
• 238000010494 dissociation reaction Methods 0.000 claims description 8
• 230000005593 dissociations Effects 0.000 claims description 8
• 241000282412 Homo Species 0.000 claims description 6
• 239000002671 adjuvant Substances 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 4
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract description 31
• 230000006052 T cell proliferation Effects 0.000 abstract description 16
• 230000016396 cytokine production Effects 0.000 abstract description 15
• 230000000295 complement effect Effects 0.000 abstract description 11
• 238000001727 in vivo Methods 0.000 abstract description 9
• 230000003213 activating effect Effects 0.000 abstract description 5
• 230000004936 stimulating effect Effects 0.000 abstract description 3
• 210000004027 cell Anatomy 0.000 description 229
• 102000025171 antigen binding proteins Human genes 0.000 description 105
• 108091000831 antigen binding proteins Proteins 0.000 description 105
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 79
• 230000000694 effects Effects 0.000 description 65
• 235000018102 proteins Nutrition 0.000 description 62
• 230000004913 activation Effects 0.000 description 42
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 42
• 230000014509 gene expression Effects 0.000 description 40
• -1 IgM Proteins 0.000 description 38
• 230000006870 function Effects 0.000 description 36
• 102000004127 Cytokines Human genes 0.000 description 34
• 108090000695 Cytokines Proteins 0.000 description 34
• 239000003112 inhibitor Substances 0.000 description 34
• 238000003556 assay Methods 0.000 description 32
• 235000001014 amino acid Nutrition 0.000 description 30
• 102000005962 receptors Human genes 0.000 description 30
• 108020003175 receptors Proteins 0.000 description 30
• 102100034980 ICOS ligand Human genes 0.000 description 29
• 239000000872 buffer Substances 0.000 description 29
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 29
• 230000001965 increasing effect Effects 0.000 description 29
• 230000035772 mutation Effects 0.000 description 29
• 239000002953 phosphate buffered saline Substances 0.000 description 29
• 239000012636 effector Substances 0.000 description 28
• 238000002955 isolation Methods 0.000 description 28
• 239000000203 mixture Substances 0.000 description 28
• 108020004414 DNA Proteins 0.000 description 26
• 238000004519 manufacturing process Methods 0.000 description 26
• 150000007523 nucleic acids Chemical class 0.000 description 26
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 25
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 25
• 229940024606 amino acid Drugs 0.000 description 25
• 150000001413 amino acids Chemical class 0.000 description 25
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 25
• 238000004458 analytical method Methods 0.000 description 23
• 210000004369 blood Anatomy 0.000 description 23
• 239000008280 blood Substances 0.000 description 23
• 238000010186 staining Methods 0.000 description 23
• 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 22
• 206010025323 Lymphomas Diseases 0.000 description 22
• 238000000684 flow cytometry Methods 0.000 description 22
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 20
• 230000001419 dependent effect Effects 0.000 description 20
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 20
• 238000006467 substitution reaction Methods 0.000 description 20
• 108091028043 Nucleic acid sequence Proteins 0.000 description 19
• 239000003814 drug Substances 0.000 description 19
• 239000013604 expression vector Substances 0.000 description 19
• 230000003993 interaction Effects 0.000 description 19
• 208000032839 leukemia Diseases 0.000 description 19
• 230000002829 reductive effect Effects 0.000 description 19
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 18
• 108060003951 Immunoglobulin Proteins 0.000 description 18
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 18
• 230000006044 T cell activation Effects 0.000 description 18
• 102000018358 immunoglobulin Human genes 0.000 description 18
• 108090000765 processed proteins & peptides Proteins 0.000 description 18
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 17
• 241000725303 Human immunodeficiency virus Species 0.000 description 17
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 17
• 239000011324 bead Substances 0.000 description 17
• 229940079593 drug Drugs 0.000 description 17
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 17
• 230000004044 response Effects 0.000 description 17
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 16
• 230000000638 stimulation Effects 0.000 description 16
• 206010065553 Bone marrow failure Diseases 0.000 description 15
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
• 241000699666 Mus <mouse, genus> Species 0.000 description 15
• 239000003085 diluting agent Substances 0.000 description 15
• 238000005516 engineering process Methods 0.000 description 15
• 239000012091 fetal bovine serum Substances 0.000 description 15
• 230000035755 proliferation Effects 0.000 description 15
• 210000003289 regulatory T cell Anatomy 0.000 description 15
• 239000000243 solution Substances 0.000 description 15
• 102000001301 EGF receptor Human genes 0.000 description 14
• 108060006698 EGF receptor Proteins 0.000 description 14
• 208000017604 Hodgkin disease Diseases 0.000 description 14
• 208000006265 Renal cell carcinoma Diseases 0.000 description 14
• 238000001514 detection method Methods 0.000 description 14
• 239000003446 ligand Substances 0.000 description 14
• 201000001441 melanoma Diseases 0.000 description 14
• 230000004048 modification Effects 0.000 description 14
• 238000012986 modification Methods 0.000 description 14
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 13
• 230000008859 change Effects 0.000 description 13
• 231100000673 dose–response relationship Toxicity 0.000 description 13
• 230000028993 immune response Effects 0.000 description 13
• 125000005647 linker group Chemical group 0.000 description 13
• 239000002609 medium Substances 0.000 description 13
• 229960003301 nivolumab Drugs 0.000 description 13
• 239000008188 pellet Substances 0.000 description 13
• 102000004196 processed proteins & peptides Human genes 0.000 description 13
• 206010006187 Breast cancer Diseases 0.000 description 12
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 12
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 12
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 12
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 12
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 12
• 229940127089 cytotoxic agent Drugs 0.000 description 12
• 238000011534 incubation Methods 0.000 description 12
• 230000002401 inhibitory effect Effects 0.000 description 12
• 230000011664 signaling Effects 0.000 description 12
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 12
• 210000001519 tissue Anatomy 0.000 description 12
• 208000026310 Breast neoplasm Diseases 0.000 description 11
• 229940045513 CTLA4 antagonist Drugs 0.000 description 11
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 11
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 11
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 11
• 150000001875 compounds Chemical class 0.000 description 11
• 239000012634 fragment Substances 0.000 description 11
• 102000039446 nucleic acids Human genes 0.000 description 11
• 108020004707 nucleic acids Proteins 0.000 description 11
• 229960002621 pembrolizumab Drugs 0.000 description 11
• 239000006228 supernatant Substances 0.000 description 11
• 241000282693 Cercopithecidae Species 0.000 description 10
• 206010009944 Colon cancer Diseases 0.000 description 10
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 10
• 206010035226 Plasma cell myeloma Diseases 0.000 description 10
• 230000022131 cell cycle Effects 0.000 description 10
• 210000003162 effector t lymphocyte Anatomy 0.000 description 10
• 239000002955 immunomodulating agent Substances 0.000 description 10
• 230000006698 induction Effects 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 229960005386 ipilimumab Drugs 0.000 description 10
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
• 229920001184 polypeptide Polymers 0.000 description 10
• 210000004881 tumor cell Anatomy 0.000 description 10
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 10
• 239000013598 vector Substances 0.000 description 10
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 9
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
• 108010074328 Interferon-gamma Proteins 0.000 description 9
• 241000124008 Mammalia Species 0.000 description 9
• 108091000080 Phosphotransferase Proteins 0.000 description 9
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 9
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 9
• 241000700605 Viruses Species 0.000 description 9
• 210000003719 b-lymphocyte Anatomy 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 230000018109 developmental process Effects 0.000 description 9
• 238000002474 experimental method Methods 0.000 description 9
• 230000013595 glycosylation Effects 0.000 description 9
• 238000006206 glycosylation reaction Methods 0.000 description 9
• 229940102223 injectable solution Drugs 0.000 description 9
• 229910052760 oxygen Inorganic materials 0.000 description 9
• 102000020233 phosphotransferase Human genes 0.000 description 9
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 8
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 8
• 238000002965 ELISA Methods 0.000 description 8
• 102100025137 Early activation antigen CD69 Human genes 0.000 description 8
• 108010087819 Fc receptors Proteins 0.000 description 8
• 102000009109 Fc receptors Human genes 0.000 description 8
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 8
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 8
• 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 8
• 101710093458 ICOS ligand Proteins 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• 241001529936 Murinae Species 0.000 description 8
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 8
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 8
• 238000007792 addition Methods 0.000 description 8
• 125000000539 amino acid group Chemical group 0.000 description 8
• 230000001900 immune effect Effects 0.000 description 8
• 229940121354 immunomodulator Drugs 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 230000003285 pharmacodynamic effect Effects 0.000 description 8
• 230000019491 signal transduction Effects 0.000 description 8
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 7
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 7
• 102100037850 Interferon gamma Human genes 0.000 description 7
• 208000034578 Multiple myelomas Diseases 0.000 description 7
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 7
• 206010033128 Ovarian cancer Diseases 0.000 description 7
• 230000018199 S phase Effects 0.000 description 7
• 210000001185 bone marrow Anatomy 0.000 description 7
• 238000004113 cell culture Methods 0.000 description 7
• 230000030833 cell death Effects 0.000 description 7
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 7
• 230000004068 intracellular signaling Effects 0.000 description 7
• GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 7
• 201000002364 leukopenia Diseases 0.000 description 7
• 231100001022 leukopenia Toxicity 0.000 description 7
• 201000000050 myeloid neoplasm Diseases 0.000 description 7
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 7
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 7
• 244000052769 pathogen Species 0.000 description 7
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 7
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 7
• 229960004641 rituximab Drugs 0.000 description 7
• 210000000952 spleen Anatomy 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 6
• 206010000830 Acute leukaemia Diseases 0.000 description 6
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 6
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 6
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 6
• 108010092160 Dactinomycin Proteins 0.000 description 6
• 102000009465 Growth Factor Receptors Human genes 0.000 description 6
• 108010009202 Growth Factor Receptors Proteins 0.000 description 6
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• 102000004889 Interleukin-6 Human genes 0.000 description 6
• 108090001005 Interleukin-6 Proteins 0.000 description 6
• 241000282567 Macaca fascicularis Species 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 6
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 6
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 6
• 206010060862 Prostate cancer Diseases 0.000 description 6
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
• 239000012980 RPMI-1640 medium Substances 0.000 description 6
• 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 6
• 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 6
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
• 102100040247 Tumor necrosis factor Human genes 0.000 description 6
• 229940122803 Vinca alkaloid Drugs 0.000 description 6
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 6
• 230000001154 acute effect Effects 0.000 description 6
• 230000033115 angiogenesis Effects 0.000 description 6
• 230000000903 blocking effect Effects 0.000 description 6
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 6
• 229960004316 cisplatin Drugs 0.000 description 6
• 238000003776 cleavage reaction Methods 0.000 description 6
• 229960000684 cytarabine Drugs 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 150000004141 diterpene derivatives Chemical class 0.000 description 6
• 229960003668 docetaxel Drugs 0.000 description 6
• 239000000975 dye Substances 0.000 description 6
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 6
• 229960002949 fluorouracil Drugs 0.000 description 6
• 201000003444 follicular lymphoma Diseases 0.000 description 6
• 108020001507 fusion proteins Proteins 0.000 description 6
• 102000037865 fusion proteins Human genes 0.000 description 6
• 229960005277 gemcitabine Drugs 0.000 description 6
• 229940088597 hormone Drugs 0.000 description 6
• 239000005556 hormone Substances 0.000 description 6
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 6
• 208000021937 marginal zone lymphoma Diseases 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 6
• 108020004999 messenger RNA Proteins 0.000 description 6
• 210000003739 neck Anatomy 0.000 description 6
• 229960002450 ofatumumab Drugs 0.000 description 6
• 230000008823 permeabilization Effects 0.000 description 6
• 230000000770 proinflammatory effect Effects 0.000 description 6
• 210000002307 prostate Anatomy 0.000 description 6
• 230000007115 recruitment Effects 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 230000007017 scission Effects 0.000 description 6
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
• 206010043554 thrombocytopenia Diseases 0.000 description 6
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 6
• 238000001890 transfection Methods 0.000 description 6
• 230000004614 tumor growth Effects 0.000 description 6
• 230000003612 virological effect Effects 0.000 description 6
• 239000011534 wash buffer Substances 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 5
• 108010006654 Bleomycin Proteins 0.000 description 5
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 5
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
• 102000003915 DNA Topoisomerases Human genes 0.000 description 5
• 108090000323 DNA Topoisomerases Proteins 0.000 description 5
• 230000006820 DNA synthesis Effects 0.000 description 5
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 5
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 5
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 5
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
• 239000004472 Lysine Substances 0.000 description 5
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
• 108091034117 Oligonucleotide Proteins 0.000 description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 description 5
• 229930012538 Paclitaxel Natural products 0.000 description 5
• 108010089430 Phosphoproteins Proteins 0.000 description 5
• 102000007982 Phosphoproteins Human genes 0.000 description 5
• 108091008611 Protein Kinase B Proteins 0.000 description 5
• 206010042971 T-cell lymphoma Diseases 0.000 description 5
• 210000000068 Th17 cell Anatomy 0.000 description 5
• 108090000704 Tubulin Proteins 0.000 description 5
• 102000004243 Tubulin Human genes 0.000 description 5
• 239000005557 antagonist Substances 0.000 description 5
• 230000000259 anti-tumor effect Effects 0.000 description 5
• 239000000074 antisense oligonucleotide Substances 0.000 description 5
• 238000012230 antisense oligonucleotides Methods 0.000 description 5
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 5
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 5
• 210000000481 breast Anatomy 0.000 description 5
• 210000004899 c-terminal region Anatomy 0.000 description 5
• 229940127093 camptothecin Drugs 0.000 description 5
• 230000004663 cell proliferation Effects 0.000 description 5
• 230000003833 cell viability Effects 0.000 description 5
• 238000005119 centrifugation Methods 0.000 description 5
• 238000010367 cloning Methods 0.000 description 5
• 239000012228 culture supernatant Substances 0.000 description 5
• 229960000640 dactinomycin Drugs 0.000 description 5
• 238000007405 data analysis Methods 0.000 description 5
• 229960000975 daunorubicin Drugs 0.000 description 5
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 5
• 230000006240 deamidation Effects 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 229960005420 etoposide Drugs 0.000 description 5
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 5
• 210000004602 germ cell Anatomy 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 210000003128 head Anatomy 0.000 description 5
• 229910052739 hydrogen Inorganic materials 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 210000001165 lymph node Anatomy 0.000 description 5
• 210000003563 lymphoid tissue Anatomy 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 5
• 229960001428 mercaptopurine Drugs 0.000 description 5
• 230000001394 metastastic effect Effects 0.000 description 5
• 206010061289 metastatic neoplasm Diseases 0.000 description 5
• 229960000485 methotrexate Drugs 0.000 description 5
• 229960001592 paclitaxel Drugs 0.000 description 5
• 238000002638 palliative care Methods 0.000 description 5
• 239000013612 plasmid Substances 0.000 description 5
• 229910052697 platinum Inorganic materials 0.000 description 5
• 230000004481 post-translational protein modification Effects 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 230000001629 suppression Effects 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 229960001278 teniposide Drugs 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 229960003087 tioguanine Drugs 0.000 description 5
• 230000009258 tissue cross reactivity Effects 0.000 description 5
• 229960000303 topotecan Drugs 0.000 description 5
• 210000003932 urinary bladder Anatomy 0.000 description 5
• 230000035899 viability Effects 0.000 description 5
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 4
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 4
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 108010074708 B7-H1 Antigen Proteins 0.000 description 4
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 4
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 208000011691 Burkitt lymphomas Diseases 0.000 description 4
• 108091007914 CDKs Proteins 0.000 description 4
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 4
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 4
• 102000003814 Interleukin-10 Human genes 0.000 description 4
• 108090000174 Interleukin-10 Proteins 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• 102000000588 Interleukin-2 Human genes 0.000 description 4
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 4
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
• 229920001213 Polysorbate 20 Polymers 0.000 description 4
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
• 102100038358 Prostate-specific antigen Human genes 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
• 108091005682 Receptor kinases Proteins 0.000 description 4
• 102000014400 SH2 domains Human genes 0.000 description 4
• 108050003452 SH2 domains Proteins 0.000 description 4
• 102000000395 SH3 domains Human genes 0.000 description 4
• 108050008861 SH3 domains Proteins 0.000 description 4
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 4
• 208000024313 Testicular Neoplasms Diseases 0.000 description 4
• 206010057644 Testis cancer Diseases 0.000 description 4
• 108091008605 VEGF receptors Proteins 0.000 description 4
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 229940100198 alkylating agent Drugs 0.000 description 4
• 239000002168 alkylating agent Substances 0.000 description 4
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 238000004422 calculation algorithm Methods 0.000 description 4
• 229960004562 carboplatin Drugs 0.000 description 4
• 229960005243 carmustine Drugs 0.000 description 4
• 229960004630 chlorambucil Drugs 0.000 description 4
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
• 239000011248 coating agent Substances 0.000 description 4
• 238000000576 coating method Methods 0.000 description 4
• 230000000139 costimulatory effect Effects 0.000 description 4
• 238000012258 culturing Methods 0.000 description 4
• 229960004397 cyclophosphamide Drugs 0.000 description 4
• 230000001472 cytotoxic effect Effects 0.000 description 4
• 230000003013 cytotoxicity Effects 0.000 description 4
• 231100000135 cytotoxicity Toxicity 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 239000012470 diluted sample Substances 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 4
• 229960004679 doxorubicin Drugs 0.000 description 4
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 4
• 210000003743 erythrocyte Anatomy 0.000 description 4
• 210000003527 eukaryotic cell Anatomy 0.000 description 4
• 230000003325 follicular Effects 0.000 description 4
• 101150023212 fut8 gene Proteins 0.000 description 4
• 229960002584 gefitinib Drugs 0.000 description 4
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 4
• 230000009033 hematopoietic malignancy Effects 0.000 description 4
• 229940022353 herceptin Drugs 0.000 description 4
• 210000004408 hybridoma Anatomy 0.000 description 4
• 230000005847 immunogenicity Effects 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 229960004768 irinotecan Drugs 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 229960001924 melphalan Drugs 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 210000000822 natural killer cell Anatomy 0.000 description 4
• 238000006386 neutralization reaction Methods 0.000 description 4
• 230000002611 ovarian Effects 0.000 description 4
• 210000001672 ovary Anatomy 0.000 description 4
• 230000003647 oxidation Effects 0.000 description 4
• 238000007254 oxidation reaction Methods 0.000 description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 210000005259 peripheral blood Anatomy 0.000 description 4
• 239000011886 peripheral blood Substances 0.000 description 4
• 230000026731 phosphorylation Effects 0.000 description 4
• 238000006366 phosphorylation reaction Methods 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 230000000284 resting effect Effects 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 210000003491 skin Anatomy 0.000 description 4
• 238000003860 storage Methods 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 201000003120 testicular cancer Diseases 0.000 description 4
• 125000003396 thiol group Chemical group [H]S* 0.000 description 4
• 229960000575 trastuzumab Drugs 0.000 description 4
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
• JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 4
• 229960003048 vinblastine Drugs 0.000 description 4
• 229960004528 vincristine Drugs 0.000 description 4
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
• 229960002066 vinorelbine Drugs 0.000 description 4
• GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
• TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 3
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
• PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 3
• 206010005003 Bladder cancer Diseases 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 108020004705 Codon Proteins 0.000 description 3
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
• 229920001917 Ficoll Polymers 0.000 description 3
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
• 241000701806 Human papillomavirus Species 0.000 description 3
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
• 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 description 3
• 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 description 3
• 102100021317 Inducible T-cell costimulator Human genes 0.000 description 3
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
• 206010027406 Mesothelioma Diseases 0.000 description 3
• 206010028116 Mucosal inflammation Diseases 0.000 description 3
• 201000010927 Mucositis Diseases 0.000 description 3
• 241000699660 Mus musculus Species 0.000 description 3
• 206010028813 Nausea Diseases 0.000 description 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 3
• 208000007452 Plasmacytoma Diseases 0.000 description 3
• 241000288906 Primates Species 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 239000012979 RPMI medium Substances 0.000 description 3
• 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
• 206010039491 Sarcoma Diseases 0.000 description 3
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
• 108091008874 T cell receptors Proteins 0.000 description 3
• 102000004338 Transferrin Human genes 0.000 description 3
• 108090000901 Transferrin Proteins 0.000 description 3
• 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
• 206010047700 Vomiting Diseases 0.000 description 3
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 3
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
• 125000002252 acyl group Chemical group 0.000 description 3
• 125000000217 alkyl group Chemical group 0.000 description 3
• 208000007502 anemia Diseases 0.000 description 3
• 230000000340 anti-metabolite Effects 0.000 description 3
• 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 3
• 229940100197 antimetabolite Drugs 0.000 description 3
• 239000002256 antimetabolite Substances 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 238000003149 assay kit Methods 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 244000052616 bacterial pathogen Species 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 229960001561 bleomycin Drugs 0.000 description 3
• 229960002092 busulfan Drugs 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 229910002091 carbon monoxide Inorganic materials 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 238000001516 cell proliferation assay Methods 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 208000037976 chronic inflammation Diseases 0.000 description 3
• 230000006020 chronic inflammation Effects 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 239000000562 conjugate Substances 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
• 229940000406 drug candidate Drugs 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 229960001433 erlotinib Drugs 0.000 description 3
• 201000004101 esophageal cancer Diseases 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• 239000003777 experimental drug Substances 0.000 description 3
• 239000012458 free base Substances 0.000 description 3
• 206010017758 gastric cancer Diseases 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 201000009277 hairy cell leukemia Diseases 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 210000002443 helper t lymphocyte Anatomy 0.000 description 3
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
• ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
• 229920000669 heparin Polymers 0.000 description 3
• PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 229940072221 immunoglobulins Drugs 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
• 238000006317 isomerization reaction Methods 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 230000036210 malignancy Effects 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 230000011278 mitosis Effects 0.000 description 3
• 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 3
• 230000008693 nausea Effects 0.000 description 3
• 108010068617 neonatal Fc receptor Proteins 0.000 description 3
• 208000004235 neutropenia Diseases 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 239000002773 nucleotide Substances 0.000 description 3
• 125000003729 nucleotide group Chemical group 0.000 description 3
• 210000000496 pancreas Anatomy 0.000 description 3
• 201000002528 pancreatic cancer Diseases 0.000 description 3
• 230000001717 pathogenic effect Effects 0.000 description 3
• 229960002087 pertuzumab Drugs 0.000 description 3
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000000861 pro-apoptotic effect Effects 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 201000001514 prostate carcinoma Diseases 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 108700042226 ras Genes Proteins 0.000 description 3
• 108010014186 ras Proteins Proteins 0.000 description 3
• 102000016914 ras Proteins Human genes 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 229960003787 sorafenib Drugs 0.000 description 3
• 210000000130 stem cell Anatomy 0.000 description 3
• 239000011550 stock solution Substances 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 239000012581 transferrin Substances 0.000 description 3
• 208000022679 triple-negative breast carcinoma Diseases 0.000 description 3
• 201000005112 urinary bladder cancer Diseases 0.000 description 3
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
• 238000002255 vaccination Methods 0.000 description 3
• 230000008673 vomiting Effects 0.000 description 3
• 239000012130 whole-cell lysate Substances 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• REEGNIYAMZUTIO-MGSMBCBTSA-N (2s)-2-[[(3r)-3-decanoyloxytetradecanoyl]amino]-3-[(2r,3r,4r,5s,6r)-3-[[(3r)-3-decanoyloxytetradecanoyl]amino]-4-[(3r)-3-decanoyloxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid Chemical compound CCCCCCCCCCC[C@@H](OC(=O)CCCCCCCCC)CC(=O)N[C@H](C(O)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCC REEGNIYAMZUTIO-MGSMBCBTSA-N 0.000 description 2
• ICLAYQQKWJGHBV-XJZMHMBSSA-N (2s)-2-[[(3r)-3-decoxytetradecanoyl]amino]-3-[(2r,3r,4r,5s,6r)-3-[[(3r)-3-decoxytetradecanoyl]amino]-4-[(3r)-3-decoxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid Chemical compound CCCCCCCCCCC[C@@H](OCCCCCCCCCC)CC(=O)N[C@H](C(O)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OCCCCCCCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OCCCCCCCCCC ICLAYQQKWJGHBV-XJZMHMBSSA-N 0.000 description 2
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
• 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
• 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 2
• YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 2
• 206010069754 Acquired gene mutation Diseases 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
• 102000051485 Bcl-2 family Human genes 0.000 description 2
• 108700038897 Bcl-2 family Proteins 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 210000005236 CD8+ effector T cell Anatomy 0.000 description 2
• 241000282836 Camelus dromedarius Species 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 102000016736 Cyclin Human genes 0.000 description 2
• 108050006400 Cyclin Proteins 0.000 description 2
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
• 125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
• 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 102400001368 Epidermal growth factor Human genes 0.000 description 2
• 101800003838 Epidermal growth factor Proteins 0.000 description 2
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
• 208000036566 Erythroleukaemia Diseases 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
• 206010064147 Gastrointestinal inflammation Diseases 0.000 description 2
• 206010018338 Glioma Diseases 0.000 description 2
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 2
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
• 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 2
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
• 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 2
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 2
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 2
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
• 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 2
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102000003816 Interleukin-13 Human genes 0.000 description 2
• 108090000176 Interleukin-13 Proteins 0.000 description 2
• 102000004388 Interleukin-4 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
• 102000017578 LAG3 Human genes 0.000 description 2
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 102000009151 Luteinizing Hormone Human genes 0.000 description 2
• 108010073521 Luteinizing Hormone Proteins 0.000 description 2
• 241000282553 Macaca Species 0.000 description 2
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
• 102000000440 Melanoma-associated antigen Human genes 0.000 description 2
• 108050008953 Melanoma-associated antigen Proteins 0.000 description 2
• 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 2
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
• 102000029749 Microtubule Human genes 0.000 description 2
• 108091022875 Microtubule Proteins 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• 208000014767 Myeloproliferative disease Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
• 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 2
• 108090000315 Protein Kinase C Proteins 0.000 description 2
• 102000003923 Protein Kinase C Human genes 0.000 description 2
• 208000009527 Refractory anemia Diseases 0.000 description 2
• 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 2
• 102000034527 Retinoid X Receptors Human genes 0.000 description 2
• 108010038912 Retinoid X Receptors Proteins 0.000 description 2
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• 108010002687 Survivin Proteins 0.000 description 2
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 108010017842 Telomerase Proteins 0.000 description 2
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
• 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
• 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
• 208000008383 Wilms tumor Diseases 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 229930183665 actinomycin Natural products 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 208000021841 acute erythroid leukemia Diseases 0.000 description 2
• 125000004423 acyloxy group Chemical group 0.000 description 2
• 230000008484 agonism Effects 0.000 description 2
• 229960000548 alemtuzumab Drugs 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
• 150000008052 alkyl sulfonates Chemical class 0.000 description 2
• 231100000360 alopecia Toxicity 0.000 description 2
• 239000003708 ampul Substances 0.000 description 2
• 208000022531 anorexia Diseases 0.000 description 2
• 229940045799 anthracyclines and related substance Drugs 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 229940044684 anti-microtubule agent Drugs 0.000 description 2
• 230000005809 anti-tumor immunity Effects 0.000 description 2
• 230000006023 anti-tumor response Effects 0.000 description 2
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
• 239000003972 antineoplastic antibiotic Substances 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 230000005975 antitumor immune response Effects 0.000 description 2
• 238000003491 array Methods 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 210000003651 basophil Anatomy 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 229960002938 bexarotene Drugs 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 210000001772 blood platelet Anatomy 0.000 description 2
• 201000008275 breast carcinoma Diseases 0.000 description 2
• 230000005907 cancer growth Effects 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000001569 carbon dioxide Substances 0.000 description 2
• 229910002092 carbon dioxide Inorganic materials 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 229960005395 cetuximab Drugs 0.000 description 2
• 238000001311 chemical methods and process Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 230000024203 complement activation Effects 0.000 description 2
• 238000002591 computed tomography Methods 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 230000009260 cross reactivity Effects 0.000 description 2
• 231100000050 cytotoxic potential Toxicity 0.000 description 2
• GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 238000013480 data collection Methods 0.000 description 2
• 206010061428 decreased appetite Diseases 0.000 description 2
• 238000010217 densitometric analysis Methods 0.000 description 2
• 238000009792 diffusion process Methods 0.000 description 2
• 238000007865 diluting Methods 0.000 description 2
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
• BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 238000006911 enzymatic reaction Methods 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 229940116977 epidermal growth factor Drugs 0.000 description 2
• 229940082789 erbitux Drugs 0.000 description 2
• 210000003238 esophagus Anatomy 0.000 description 2
• HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 229960005167 everolimus Drugs 0.000 description 2
• 229960000255 exemestane Drugs 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 150000002190 fatty acyls Chemical group 0.000 description 2
• 229940126864 fibroblast growth factor Drugs 0.000 description 2
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
• 229960000961 floxuridine Drugs 0.000 description 2
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
• 229940028334 follicle stimulating hormone Drugs 0.000 description 2
• 210000000285 follicular dendritic cell Anatomy 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 208000018925 gastrointestinal mucositis Diseases 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 210000001280 germinal center Anatomy 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
• 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
• 230000002489 hematologic effect Effects 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 238000007489 histopathology method Methods 0.000 description 2
• 239000002944 hormone and hormone analog Substances 0.000 description 2
• 230000036571 hydration Effects 0.000 description 2
• 238000006703 hydration reaction Methods 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 230000004957 immunoregulator effect Effects 0.000 description 2
• 239000003022 immunostimulating agent Substances 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 229960000367 inositol Drugs 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 229960004891 lapatinib Drugs 0.000 description 2
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 230000021633 leukocyte mediated immunity Effects 0.000 description 2
• 108020001756 ligand binding domains Proteins 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 229940040129 luteinizing hormone Drugs 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 230000000527 lymphocytic effect Effects 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• 201000004792 malaria Diseases 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 201000000248 mediastinal malignant lymphoma Diseases 0.000 description 2
• ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 2
• 208000021039 metastatic melanoma Diseases 0.000 description 2
• 239000011325 microbead Substances 0.000 description 2
• 210000004688 microtubule Anatomy 0.000 description 2
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
• 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 210000005087 mononuclear cell Anatomy 0.000 description 2
• 210000004400 mucous membrane Anatomy 0.000 description 2
• 206010028537 myelofibrosis Diseases 0.000 description 2
• 230000009826 neoplastic cell growth Effects 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• 238000012856 packing Methods 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 210000004180 plasmocyte Anatomy 0.000 description 2
• 229920001993 poloxamer 188 Polymers 0.000 description 2
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
• 238000011533 pre-incubation Methods 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• 230000009465 prokaryotic expression Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 150000003212 purines Chemical class 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 238000002708 random mutagenesis Methods 0.000 description 2
• 230000007420 reactivation Effects 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000021014 regulation of cell growth Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 102000003702 retinoic acid receptors Human genes 0.000 description 2
• 108090000064 retinoic acid receptors Proteins 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 238000007363 ring formation reaction Methods 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
• 238000009094 second-line therapy Methods 0.000 description 2
• 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
• 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 208000013223 septicemia Diseases 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 230000037439 somatic mutation Effects 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• 201000011549 stomach cancer Diseases 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 230000002483 superagonistic effect Effects 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 101150047061 tag-72 gene Proteins 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 229960000235 temsirolimus Drugs 0.000 description 2
• 230000002381 testicular Effects 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 230000036962 time dependent Effects 0.000 description 2
• 238000004448 titration Methods 0.000 description 2
• 238000011830 transgenic mouse model Methods 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 102000035160 transmembrane proteins Human genes 0.000 description 2
• 108091005703 transmembrane proteins Proteins 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 150000004654 triazenes Chemical class 0.000 description 2
• 239000012137 tryptone Substances 0.000 description 2
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
• 241001529453 unidentified herpesvirus Species 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• 239000012646 vaccine adjuvant Substances 0.000 description 2
• 229940124931 vaccine adjuvant Drugs 0.000 description 2
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 238000002424 x-ray crystallography Methods 0.000 description 2
• HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
• JNSWIYCWZPFQQF-JGVFFNPUSA-N (2r,3s)-3-(carboxyamino)-2-hydroxy-3-phenylpropanoic acid Chemical compound OC(=O)[C@H](O)[C@@H](NC(O)=O)C1=CC=CC=C1 JNSWIYCWZPFQQF-JGVFFNPUSA-N 0.000 description 1
• HYJVYOWKYPNSTK-UONOGXRCSA-N (2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoic acid Chemical compound N([C@H]([C@@H](O)C(O)=O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 HYJVYOWKYPNSTK-UONOGXRCSA-N 0.000 description 1
• PRIXXGNJDNLMBH-DPGPRPECSA-N (2s)-2-[[(3r)-3-hexanoyloxytetradecanoyl]amino]-3-[(2r,3r,4r,5s,6r)-3-[[(3r)-3-hexanoyloxytetradecanoyl]amino]-4-[(3r)-3-hexanoyloxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid Chemical compound CCCCCCCCCCC[C@@H](OC(=O)CCCCC)CC(=O)N[C@H](C(O)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCC PRIXXGNJDNLMBH-DPGPRPECSA-N 0.000 description 1
• VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
• XCLSNQRIRMTTPT-UHFFFAOYSA-N 2-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine Chemical compound N=1C(N)=C2C=C(OCCOC)C(OCCOC)=CC2=NC=1C1=CC=CC(C#C)=C1 XCLSNQRIRMTTPT-UHFFFAOYSA-N 0.000 description 1
• KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
• ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
• LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
• IMXHGCRIEAKIBU-UHFFFAOYSA-N 4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC3)C(=O)OC)C2=N1 IMXHGCRIEAKIBU-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 1
• 101710163573 5-hydroxyisourate hydrolase Proteins 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 208000023761 AL amyloidosis Diseases 0.000 description 1
• BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
• 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
• KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 description 1
• 241000235389 Absidia Species 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 244000303258 Annona diversifolia Species 0.000 description 1
• 235000002198 Annona diversifolia Nutrition 0.000 description 1
• 101710145634 Antigen 1 Proteins 0.000 description 1
• 101100402572 Arabidopsis thaliana MS5 gene Proteins 0.000 description 1
• 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
• 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 241000238017 Astacoidea Species 0.000 description 1
• 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 241000193738 Bacillus anthracis Species 0.000 description 1
• 241001235572 Balantioides coli Species 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 102000015735 Beta-catenin Human genes 0.000 description 1
• 108060000903 Beta-catenin Proteins 0.000 description 1
• 241000228405 Blastomyces dermatitidis Species 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 208000003508 Botulism Diseases 0.000 description 1
• 206010055113 Breast cancer metastatic Diseases 0.000 description 1
• 108090000342 C-Type Lectins Proteins 0.000 description 1
• 102000003930 C-Type Lectins Human genes 0.000 description 1
• 241000282832 Camelidae Species 0.000 description 1
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
• 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
• 102000013392 Carboxylesterase Human genes 0.000 description 1
• 108010051152 Carboxylesterase Proteins 0.000 description 1
• 108010006303 Carboxypeptidases Proteins 0.000 description 1
• 102000005367 Carboxypeptidases Human genes 0.000 description 1
• 208000005024 Castleman disease Diseases 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 108010059013 Chaperonin 10 Proteins 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
• 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 241000223205 Coccidioides immitis Species 0.000 description 1
• 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
• 241000711573 Coronaviridae Species 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 208000012609 Cowden disease Diseases 0.000 description 1
• 241000709687 Coxsackievirus Species 0.000 description 1
• 206010011409 Cross infection Diseases 0.000 description 1
• 201000007336 Cryptococcosis Diseases 0.000 description 1
• 241000221204 Cryptococcus neoformans Species 0.000 description 1
• 241000223935 Cryptosporidium Species 0.000 description 1
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
• 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
• 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
• 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
• 108010072210 Cyclophilin C Proteins 0.000 description 1
• 206010050685 Cytokine storm Diseases 0.000 description 1
• 231100001074 DNA strand break Toxicity 0.000 description 1
• 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
• 241000725619 Dengue virus Species 0.000 description 1
• 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 1
• 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 241001466953 Echovirus Species 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 102100038083 Endosialin Human genes 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 241000224432 Entamoeba histolytica Species 0.000 description 1
• 241000709661 Enterovirus Species 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 102000050554 Eph Family Receptors Human genes 0.000 description 1
• 108091008815 Eph receptors Proteins 0.000 description 1
• 102100023721 Ephrin-B2 Human genes 0.000 description 1
• 108010044090 Ephrin-B2 Proteins 0.000 description 1
• 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 101100129915 Escherichia coli (strain K12) melB gene Proteins 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• 235000006149 Eugenia stipitata Nutrition 0.000 description 1
• 240000005708 Eugenia stipitata Species 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 208000001382 Experimental Melanoma Diseases 0.000 description 1
• 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
• 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
• 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
• 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
• 102100037362 Fibronectin Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 241000192125 Firmicutes Species 0.000 description 1
• 241000710831 Flavivirus Species 0.000 description 1
• 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 1
• 102000006471 Fucosyltransferases Human genes 0.000 description 1
• 108010019236 Fucosyltransferases Proteins 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 230000010337 G2 phase Effects 0.000 description 1
• 101710113436 GTPase KRas Proteins 0.000 description 1
• 102100040510 Galectin-3-binding protein Human genes 0.000 description 1
• 101710197901 Galectin-3-binding protein Proteins 0.000 description 1
• 102100039554 Galectin-8 Human genes 0.000 description 1
• 206010061968 Gastric neoplasm Diseases 0.000 description 1
• 208000034951 Genetic Translocation Diseases 0.000 description 1
• 108010026318 Geranyltranstransferase Proteins 0.000 description 1
• 102000013404 Geranyltranstransferase Human genes 0.000 description 1
• 241000224466 Giardia Species 0.000 description 1
• 241000251152 Ginglymostoma cirratum Species 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 108010069236 Goserelin Proteins 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 206010053759 Growth retardation Diseases 0.000 description 1
• 239000004010 HER dimerization inhibitor Substances 0.000 description 1
• 102000006354 HLA-DR Antigens Human genes 0.000 description 1
• 108010058597 HLA-DR Antigens Proteins 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
• 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
• 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 1
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
• 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 1
• 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 description 1
• 101000884275 Homo sapiens Endosialin Proteins 0.000 description 1
• 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 1
• 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101001037147 Homo sapiens Immunoglobulin heavy variable 1-69 Proteins 0.000 description 1
• 101001047617 Homo sapiens Immunoglobulin kappa variable 3-11 Proteins 0.000 description 1
• 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
• 101000578943 Homo sapiens MAGE-like protein 2 Proteins 0.000 description 1
• 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 1
• 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
• 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
• 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 1
• 101001005725 Homo sapiens Melanoma-associated antigen 10 Proteins 0.000 description 1
• 101001005716 Homo sapiens Melanoma-associated antigen 11 Proteins 0.000 description 1
• 101001005717 Homo sapiens Melanoma-associated antigen 12 Proteins 0.000 description 1
• 101001005718 Homo sapiens Melanoma-associated antigen 2 Proteins 0.000 description 1
• 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 description 1
• 101001005722 Homo sapiens Melanoma-associated antigen 6 Proteins 0.000 description 1
• 101001005723 Homo sapiens Melanoma-associated antigen 8 Proteins 0.000 description 1
• 101001005724 Homo sapiens Melanoma-associated antigen 9 Proteins 0.000 description 1
• 101001036682 Homo sapiens Melanoma-associated antigen B18 Proteins 0.000 description 1
• 101001036675 Homo sapiens Melanoma-associated antigen B6 Proteins 0.000 description 1
• 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 1
• 101001057154 Homo sapiens Melanoma-associated antigen D2 Proteins 0.000 description 1
• 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 description 1
• 101001057137 Homo sapiens Melanoma-associated antigen E1 Proteins 0.000 description 1
• 101001057135 Homo sapiens Melanoma-associated antigen H1 Proteins 0.000 description 1
• 101000880402 Homo sapiens Metalloreductase STEAP4 Proteins 0.000 description 1
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
• 101000633310 Homo sapiens Nuclear receptor-interacting protein 3 Proteins 0.000 description 1
• 101001121964 Homo sapiens OCIA domain-containing protein 1 Proteins 0.000 description 1
• 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
• 101000625256 Homo sapiens Protein Mis18-beta Proteins 0.000 description 1
• 101000880775 Homo sapiens Protein SSX5 Proteins 0.000 description 1
• 101000735459 Homo sapiens Protein mono-ADP-ribosyltransferase PARP9 Proteins 0.000 description 1
• 101000685275 Homo sapiens Protein sel-1 homolog 1 Proteins 0.000 description 1
• 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 description 1
• 101001106322 Homo sapiens Rho GTPase-activating protein 7 Proteins 0.000 description 1
• 101000973629 Homo sapiens Ribosome quality control complex subunit NEMF Proteins 0.000 description 1
• 101000650621 Homo sapiens Septin-1 Proteins 0.000 description 1
• 101000740529 Homo sapiens Serologically defined colon cancer antigen 8 Proteins 0.000 description 1
• 101000825253 Homo sapiens Sperm protein associated with the nucleus on the X chromosome A Proteins 0.000 description 1
• 101000625821 Homo sapiens TBC1 domain family member 2A Proteins 0.000 description 1
• 101000847107 Homo sapiens Tetraspanin-8 Proteins 0.000 description 1
• 101000671653 Homo sapiens U3 small nucleolar RNA-associated protein 14 homolog A Proteins 0.000 description 1
• 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 1
• 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
• 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 108010052919 Hydroxyethylthiazole kinase Proteins 0.000 description 1
• 108010027436 Hydroxymethylpyrimidine kinase Proteins 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 101150016644 ICOSLG gene Proteins 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
• 101150057269 IKBKB gene Proteins 0.000 description 1
• JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
• 206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
• 102100040232 Immunoglobulin heavy variable 1-69 Human genes 0.000 description 1
• 102100022955 Immunoglobulin kappa variable 3-11 Human genes 0.000 description 1
• 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
• 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
• 101710205775 Inducible T-cell costimulator Proteins 0.000 description 1
• 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
• 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
• 108010030506 Integrin alpha6beta4 Proteins 0.000 description 1
• 102100025390 Integrin beta-2 Human genes 0.000 description 1
• 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
• 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 241000701460 JC polyomavirus Species 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
• 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 108010001831 LDL receptors Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 241000282852 Lama guanicoe Species 0.000 description 1
• 241001245510 Lambia <signal fly> Species 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 241000222727 Leishmania donovani Species 0.000 description 1
• 208000004554 Leishmaniasis Diseases 0.000 description 1
• 206010024238 Leptospirosis Diseases 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 208000035561 Leukaemic infiltration brain Diseases 0.000 description 1
• 108010028275 Leukocyte Elastase Proteins 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
• 102000019298 Lipocalin Human genes 0.000 description 1
• 108050006654 Lipocalin Proteins 0.000 description 1
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
• 102100028333 MAGE-like protein 2 Human genes 0.000 description 1
• 201000003791 MALT lymphoma Diseases 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
• 102100025136 Macrosialin Human genes 0.000 description 1
• 206010064912 Malignant transformation Diseases 0.000 description 1
• 241000282342 Martes americana Species 0.000 description 1
• 241000712079 Measles morbillivirus Species 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
• 102100025049 Melanoma-associated antigen 10 Human genes 0.000 description 1
• 102100025083 Melanoma-associated antigen 11 Human genes 0.000 description 1
• 102100025084 Melanoma-associated antigen 12 Human genes 0.000 description 1
• 102100025081 Melanoma-associated antigen 2 Human genes 0.000 description 1
• 102100025077 Melanoma-associated antigen 4 Human genes 0.000 description 1
• 102100025075 Melanoma-associated antigen 6 Human genes 0.000 description 1
• 102100025076 Melanoma-associated antigen 8 Human genes 0.000 description 1
• 102100025079 Melanoma-associated antigen 9 Human genes 0.000 description 1
• 102100039478 Melanoma-associated antigen B18 Human genes 0.000 description 1
• 102100039483 Melanoma-associated antigen B6 Human genes 0.000 description 1
• 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 1
• 102100027251 Melanoma-associated antigen D2 Human genes 0.000 description 1
• 102100027257 Melanoma-associated antigen D4 Human genes 0.000 description 1
• 102100027256 Melanoma-associated antigen H1 Human genes 0.000 description 1
• 102100037258 Membrane-associated transporter protein Human genes 0.000 description 1
• 102000003735 Mesothelin Human genes 0.000 description 1
• 108090000015 Mesothelin Proteins 0.000 description 1
• 102100037654 Metalloreductase STEAP4 Human genes 0.000 description 1
• 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
• 208000003445 Mouth Neoplasms Diseases 0.000 description 1
• 241000235395 Mucor Species 0.000 description 1
• 241000235388 Mucorales Species 0.000 description 1
• 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
• 208000010718 Multiple Organ Failure Diseases 0.000 description 1
• 241000711386 Mumps virus Species 0.000 description 1
• 101001033276 Mus musculus Interleukin-3 Proteins 0.000 description 1
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
• 206010028561 Myeloid metaplasia Diseases 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 101150111783 NTRK1 gene Proteins 0.000 description 1
• 101150117329 NTRK3 gene Proteins 0.000 description 1
• 241000224438 Naegleria fowleri Species 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 206010029155 Nephropathy toxic Diseases 0.000 description 1
• 102100033174 Neutrophil elastase Human genes 0.000 description 1
• 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 1
• 241001126259 Nippostrongylus brasiliensis Species 0.000 description 1
• 206010029803 Nosocomial infection Diseases 0.000 description 1
• 101150056950 Ntrk2 gene Proteins 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• 102100029561 Nuclear receptor-interacting protein 3 Human genes 0.000 description 1
• 102100027183 OCIA domain-containing protein 1 Human genes 0.000 description 1
• 102000004473 OX40 Ligand Human genes 0.000 description 1
• 108010042215 OX40 Ligand Proteins 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 239000012124 Opti-MEM Substances 0.000 description 1
• 206010033109 Ototoxicity Diseases 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 101150093908 PDGFRB gene Proteins 0.000 description 1
• 102000000470 PDZ domains Human genes 0.000 description 1
• 108050008994 PDZ domains Proteins 0.000 description 1
• 229910018828 PO3H2 Inorganic materials 0.000 description 1
• 102000036673 PRAME Human genes 0.000 description 1
• 108060006580 PRAME Proteins 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
• 208000002774 Paraproteinemias Diseases 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010079855 Peptide Aptamers Proteins 0.000 description 1
• 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 206010035148 Plague Diseases 0.000 description 1
• 241000233872 Pneumocystis carinii Species 0.000 description 1
• 244000236480 Podophyllum peltatum Species 0.000 description 1
• 208000000474 Poliomyelitis Diseases 0.000 description 1
• 208000004880 Polyuria Diseases 0.000 description 1
• 206010036673 Primary amyloidosis Diseases 0.000 description 1
• 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102100025034 Protein Mis18-beta Human genes 0.000 description 1
• 102100037723 Protein SSX5 Human genes 0.000 description 1
• 102100034930 Protein mono-ADP-ribosyltransferase PARP9 Human genes 0.000 description 1
• 102100023159 Protein sel-1 homolog 1 Human genes 0.000 description 1
• 241000588769 Proteus <enterobacteria> Species 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 101710186755 Putative pterin-4-alpha-carbinolamine dehydratase 1 Proteins 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 101150004107 REG3A gene Proteins 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 241000711798 Rabies lyssavirus Species 0.000 description 1
• 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
• 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
• 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 241000725643 Respiratory syncytial virus Species 0.000 description 1
• 102100021446 Rho GTPase-activating protein 7 Human genes 0.000 description 1
• 102000003861 Ribosomal protein S6 Human genes 0.000 description 1
• 108090000221 Ribosomal protein S6 Proteins 0.000 description 1
• 102100022213 Ribosome quality control complex subunit NEMF Human genes 0.000 description 1
• 241000606651 Rickettsiales Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 241000702670 Rotavirus Species 0.000 description 1
• 241000710799 Rubella virus Species 0.000 description 1
• 108091007563 SLC45A2 Proteins 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 102100027698 Septin-1 Human genes 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102100037221 Serologically defined colon cancer antigen 8 Human genes 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
• 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 102100037253 Solute carrier family 45 member 3 Human genes 0.000 description 1
• 102100022327 Sperm protein associated with the nucleus on the X chromosome A Human genes 0.000 description 1
• 241001149962 Sporothrix Species 0.000 description 1
• 241000295644 Staphylococcaceae Species 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 1
• 241001147844 Streptomyces verticillus Species 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
• 108091008035 T cell costimulatory receptors Proteins 0.000 description 1
• 230000037453 T cell priming Effects 0.000 description 1
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
• 102100024767 TBC1 domain family member 2A Human genes 0.000 description 1
• 108091005735 TGF-beta receptors Proteins 0.000 description 1
• 101150031162 TM4SF1 gene Proteins 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 241001116498 Taxus baccata Species 0.000 description 1
• 241000015728 Taxus canadensis Species 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 102100024554 Tetranectin Human genes 0.000 description 1
• 102100032802 Tetraspanin-8 Human genes 0.000 description 1
• 208000005485 Thrombocytosis Diseases 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 102100033504 Thyroglobulin Human genes 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 101710183280 Topoisomerase Proteins 0.000 description 1
• 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
• 241000223996 Toxoplasma Species 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 108010033576 Transferrin Receptors Proteins 0.000 description 1
• 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
• 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
• 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 description 1
• LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
• 241000223105 Trypanosoma brucei Species 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
• 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
• 102000003425 Tyrosinase Human genes 0.000 description 1
• 108060008724 Tyrosinase Proteins 0.000 description 1
• 102100040099 U3 small nucleolar RNA-associated protein 14 homolog A Human genes 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 241001416177 Vicugna pacos Species 0.000 description 1
• 241000863480 Vinca Species 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 102100039490 X antigen family member 1 Human genes 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 description 1
• 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
• 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
• 102000035181 adaptor proteins Human genes 0.000 description 1
• 108091005764 adaptor proteins Proteins 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000009824 affinity maturation Effects 0.000 description 1
• 229940042992 afinitor Drugs 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 229940098174 alkeran Drugs 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• 206010002022 amyloidosis Diseases 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000001745 anti-biotin effect Effects 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000003432 anti-folate effect Effects 0.000 description 1
• 230000001946 anti-microtubular Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 239000000611 antibody drug conjugate Substances 0.000 description 1
• 229940049595 antibody-drug conjugate Drugs 0.000 description 1
• 229940127074 antifolate Drugs 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 238000002820 assay format Methods 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 208000007456 balantidiasis Diseases 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 229940108502 bicnu Drugs 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 210000003969 blast cell Anatomy 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000000621 bronchi Anatomy 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229940112129 campath Drugs 0.000 description 1
• 229940088954 camptosar Drugs 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
• 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 230000006652 catabolic pathway Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
• 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
• 101150116749 chuk gene Proteins 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 1
• 230000010405 clearance mechanism Effects 0.000 description 1
• 238000007621 cluster analysis Methods 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000011220 combination immunotherapy Methods 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 238000000205 computational method Methods 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229940088547 cosmegen Drugs 0.000 description 1
• CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 1
• PWOQRKCAHTVFLB-UHFFFAOYSA-N cyclophosphamide hydrate Chemical compound O.ClCCN(CCCl)P1(=O)NCCCO1 PWOQRKCAHTVFLB-UHFFFAOYSA-N 0.000 description 1
• 229960000978 cyproterone acetate Drugs 0.000 description 1
• UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
• 206010052015 cytokine release syndrome Diseases 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 231100000517 death Toxicity 0.000 description 1
• 239000008367 deionised water Substances 0.000 description 1
• 229910021641 deionized water Inorganic materials 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 150000004985 diamines Chemical class 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 229930004069 diterpene Natural products 0.000 description 1
• 230000035619 diuresis Effects 0.000 description 1
• 230000005782 double-strand break Effects 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
• 229960004199 dutasteride Drugs 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 229940121647 egfr inhibitor Drugs 0.000 description 1
• 239000012039 electrophile Substances 0.000 description 1
• 230000009881 electrostatic interaction Effects 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 229940007078 entamoeba histolytica Drugs 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 102000015694 estrogen receptors Human genes 0.000 description 1
• 108010038795 estrogen receptors Proteins 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000008175 fetal development Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
• 229960004039 finasteride Drugs 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• 229960005304 fludarabine phosphate Drugs 0.000 description 1
• 150000005699 fluoropyrimidines Chemical class 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• 208000024386 fungal infectious disease Diseases 0.000 description 1
• 244000053095 fungal pathogen Species 0.000 description 1
• 229940084434 fungoid Drugs 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 102000013069 gamma-Crystallins Human genes 0.000 description 1
• 108010079934 gamma-Crystallins Proteins 0.000 description 1
• 208000010749 gastric carcinoma Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000001641 gel filtration chromatography Methods 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• OKKDEIYWILRZIA-OSZBKLCCSA-N gemcitabine hydrochloride Chemical compound [H+].[Cl-].O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 OKKDEIYWILRZIA-OSZBKLCCSA-N 0.000 description 1
• 229940020967 gemzar Drugs 0.000 description 1
• 210000004392 genitalia Anatomy 0.000 description 1
• 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000012178 germinal center formation Effects 0.000 description 1
• 201000006592 giardiasis Diseases 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
• 229960003690 goserelin acetate Drugs 0.000 description 1
• 210000000224 granular leucocyte Anatomy 0.000 description 1
• 101150098203 grb2 gene Proteins 0.000 description 1
• 230000036433 growing body Effects 0.000 description 1
• 231100000001 growth retardation Toxicity 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 201000003911 head and neck carcinoma Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000005252 hepatitis A Diseases 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 238000010562 histological examination Methods 0.000 description 1
• 102000046492 human ICOSLG Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
• 108010003425 hyaluronan-mediated motility receptor Proteins 0.000 description 1
• 229940088013 hycamtin Drugs 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 238000011502 immune monitoring Methods 0.000 description 1
• 230000037451 immune surveillance Effects 0.000 description 1
• 230000002871 immunocytoma Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 210000002602 induced regulatory T cell Anatomy 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 108091008042 inhibitory receptors Proteins 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000010212 intracellular staining Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 229940084651 iressa Drugs 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 238000012933 kinetic analysis Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 229960003881 letrozole Drugs 0.000 description 1
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
• 229940063725 leukeran Drugs 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 235000015250 liver sausages Nutrition 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
• 238000002794 lymphocyte assay Methods 0.000 description 1
• 208000025036 lymphosarcoma Diseases 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 101150103001 mEFG1 gene Proteins 0.000 description 1
• 229940124302 mTOR inhibitor Drugs 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000036212 malign transformation Effects 0.000 description 1
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
• 241001515942 marmosets Species 0.000 description 1
• 201000006512 mast cell neoplasm Diseases 0.000 description 1
• 208000006971 mastocytoma Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• WFFQYWAAEWLHJC-UHFFFAOYSA-N mercaptopurine hydrate Chemical compound O.S=C1NC=NC2=C1NC=N2 WFFQYWAAEWLHJC-UHFFFAOYSA-N 0.000 description 1
• 229960005558 mertansine Drugs 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 230000031864 metaphase Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
• DASQOOZCTWOQPA-GXKRWWSZSA-L methotrexate disodium Chemical compound [Na+].[Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 DASQOOZCTWOQPA-GXKRWWSZSA-L 0.000 description 1
• VDOCQQKGPJENHJ-UHFFFAOYSA-N methyl n-[4-[4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC=4C=NC=CC=4)CC3)C2=N1 VDOCQQKGPJENHJ-UHFFFAOYSA-N 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000002625 monoclonal antibody therapy Methods 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 229940124303 multikinase inhibitor Drugs 0.000 description 1
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
• BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 208000025402 neoplasm of esophagus Diseases 0.000 description 1
• 208000025440 neoplasm of neck Diseases 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 230000007694 nephrotoxicity Effects 0.000 description 1
• 229940080607 nexavar Drugs 0.000 description 1
• 229960002653 nilutamide Drugs 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 230000000269 nucleophilic effect Effects 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000004768 organ dysfunction Effects 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 231100000262 ototoxicity Toxicity 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 238000002559 palpation Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 210000004976 peripheral blood cell Anatomy 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 210000001986 peyer's patch Anatomy 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 208000031223 plasma cell leukemia Diseases 0.000 description 1
• 229940063179 platinol Drugs 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 208000030761 polycystic kidney disease Diseases 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
• 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 239000000092 prognostic biomarker Substances 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 108010079891 prostein Proteins 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 239000003531 protein hydrolysate Substances 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 239000002213 purine nucleotide Substances 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
• 108010077182 raf Kinases Proteins 0.000 description 1
• 102000009929 raf Kinases Human genes 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 108091006082 receptor inhibitors Proteins 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 208000020615 rectal carcinoma Diseases 0.000 description 1
• 238000007100 recyclization reaction Methods 0.000 description 1
• 239000001044 red dye Substances 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000025053 regulation of cell proliferation Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 210000001995 reticulocyte Anatomy 0.000 description 1
• 102000027483 retinoid hormone receptors Human genes 0.000 description 1
• 108091008679 retinoid hormone receptors Proteins 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 229960001302 ridaforolimus Drugs 0.000 description 1
• XYSQXZCMOLNHOI-UHFFFAOYSA-N s-[2-[[4-(acetylsulfamoyl)phenyl]carbamoyl]phenyl] 5-pyridin-1-ium-1-ylpentanethioate;bromide Chemical compound [Br-].C1=CC(S(=O)(=O)NC(=O)C)=CC=C1NC(=O)C1=CC=CC=C1SC(=O)CCCC[N+]1=CC=CC=C1 XYSQXZCMOLNHOI-UHFFFAOYSA-N 0.000 description 1
• 239000002795 scorpion venom Substances 0.000 description 1
• 150000003354 serine derivatives Chemical class 0.000 description 1
• 235000015170 shellfish Nutrition 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 238000004513 sizing Methods 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 102000009076 src-Family Kinases Human genes 0.000 description 1
• 108010087686 src-Family Kinases Proteins 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 230000001839 systemic circulation Effects 0.000 description 1
• 230000008718 systemic inflammatory response Effects 0.000 description 1
• 229940095374 tabloid Drugs 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 229940120982 tarceva Drugs 0.000 description 1
• 229940099419 targretin Drugs 0.000 description 1
• 150000004579 taxol derivatives Chemical class 0.000 description 1
• RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
• 235000007586 terpenes Nutrition 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 108010013645 tetranectin Proteins 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000031998 transcytosis Effects 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 229960001612 trastuzumab emtansine Drugs 0.000 description 1
• 108010020589 trehalose-6-phosphate synthase Proteins 0.000 description 1
• 229950007217 tremelimumab Drugs 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
• AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002166 vinorelbine tartrate Drugs 0.000 description 1
• GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1